Condition: Type 1 Diabetes (T1D) · Type 2 Diabetes (T2D) · Sponsor: DreaMed Diabetes
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily insulin injections (MDI), or with type 2 diabetes (T2D) who use MDI, basal insulin only, or who are candidates to initiate basal insulin, in conjunction with continuous glucose monitoring (CGM).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| SUNY Upstate Medical Center | Albany, New York, United States | Recruiting |
| Texas Diabetes & Endocrinology | Austin, Texas, United States | Recruiting |
| Diabetes & Endocrine Treatment Specialisits (DETS) | Sandy City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07599982